2016
DOI: 10.1016/bs.pbr.2015.07.026
|View full text |Cite
|
Sign up to set email alerts
|

Genetic imaging consortium for addiction medicine

Abstract: Since the sample size of a typical neuroimaging study lacks sufficient statistical power to explore unknown genomic associations with brain phenotypes, several international genetic imaging consortia have been organized in recent years to pool data across sites. The challenges and achievements of these consortia are considered here with the goal of leveraging these resources to study addiction. The authors of this review have joined together to form an Addiction working group within the framework of the ENIGMA… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
13
0

Year Published

2016
2016
2020
2020

Publication Types

Select...
5
5

Relationship

4
6

Authors

Journals

citations
Cited by 22 publications
(13 citation statements)
references
References 74 publications
0
13
0
Order By: Relevance
“…The increasing potency of cannabis, rates of treatment-seeking users, and availability of cannabis products due to recent decriminalization policies warrant the identification of vulnerability factors within cannabis users for adverse neurobiological outcomes, such that targeted prevention and intervention strategies may be developed. We warrant the examination of large-scale adult and adolescent samples from existing consortia collating genetic, neural, and behavioral data (ENIGMA Addiction 86 and IMAGEN ) 87 to study the role of additional genetic polymorphisms (e.g., CNR1) and nongenetic factors on neuroanatomy (e.g., mental health, socioeconomic status, comorbid substance use, and cannabinoid compounds), and psychosocial outcomes in cannabis users, and to ultimately minimize cannabis-related harms.…”
Section: Discussionmentioning
confidence: 99%
“…The increasing potency of cannabis, rates of treatment-seeking users, and availability of cannabis products due to recent decriminalization policies warrant the identification of vulnerability factors within cannabis users for adverse neurobiological outcomes, such that targeted prevention and intervention strategies may be developed. We warrant the examination of large-scale adult and adolescent samples from existing consortia collating genetic, neural, and behavioral data (ENIGMA Addiction 86 and IMAGEN ) 87 to study the role of additional genetic polymorphisms (e.g., CNR1) and nongenetic factors on neuroanatomy (e.g., mental health, socioeconomic status, comorbid substance use, and cannabinoid compounds), and psychosocial outcomes in cannabis users, and to ultimately minimize cannabis-related harms.…”
Section: Discussionmentioning
confidence: 99%
“…The ENIGMA-Addictions/SUDs WG has 33 participating sites, contributing MRI data from 12,347 individuals of whom 2277 are adult patients with SUD relating to one of five substances (alcohol, nicotine, cocaine, methamphetamine, or cannabis) 5,84,85 . In these data, Mackey 5 observed lower cortical thickness/subcortical volume in cases relative to controls in regions that play key roles in evaluating reward (MOFC, amygdala), task monitoring (superior frontal cortex), attention (superior parietal cortex, posterior cingulate) and perception/regulation of internal body states (insula).…”
Section: Enigma-addictions/sudmentioning
confidence: 99%
“…These considerations along with the modern developed multidisciplinary investigation methods, such as genetic imaging, would be a suitable approach to complement other cellular, molecular, and genetic approaches (Mackey et al, 2016).…”
Section: Precision Medicinementioning
confidence: 99%